{"nctId":"NCT02062502","briefTitle":"Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)","startDateStruct":{"date":"2014-03-07","type":"ACTUAL"},"conditions":["Varicella"],"count":611,"armGroups":[{"label":"VARIVAX™ NSP + M-M-R II™","type":"EXPERIMENTAL","interventionNames":["Biological: VARIVAX™ New Seed Process","Biological: M-M-R II™"]},{"label":"VARIVAX™ 2007 Process + M-M-R II™","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: VARIVAX™ 2007 process","Biological: M-M-R II™"]}],"interventions":[{"name":"VARIVAX™ New Seed Process","otherNames":[]},{"name":"VARIVAX™ 2007 process","otherNames":[]},{"name":"M-M-R II™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella\n\nExclusion Criteria:\n\n* Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study\n* Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity\n* Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study\n* History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX™ or M-M-R II™\n* Received salicylates within 14 days prior to study vaccination\n* Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination\n* Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination\n* History of seizure disorder, including febrile seizure\n* Fever illness (\\>=102.2 °F \\[39.0 °C\\] within 72 hours prior to study vaccination\n* History of thrombocytopenia\n* Born to a human immunodeficiency virus (HIV)-infected mother\n* Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"23 Months","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer of VZV Antibodies","description":"Antibody titers were measured with gpELISA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.28","spread":null},{"groupId":"OG001","value":"17.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Fever (>=102.2 °F Oral Equivalent)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Systemic Measles-like, Rubella-like, Varicella-like Rash, Mumps-like Symptoms, and Injection-site Rash After Vaccination 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Systemic Measles-like, Rubella-like, Varicella-like Rash, Mumps-like Symptoms, and Injection-site Rash After Vaccination 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Injection-site Erythema, Injection-site Swelling, and Injection-site Pain/Tenderness After Vaccination 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.3","spread":null},{"groupId":"OG001","value":"19.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":null},{"groupId":"OG001","value":"28.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Solicited Injection-site Erythema, Injection-site Swelling, and Injection-site Pain/Tenderness After Vaccination 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"22.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"24.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":291},"commonTop":["Injection site pain","Injection site erythema","Injection site swelling","Pyrexia","Upper respiratory tract infection"]}}}